Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Neumora Therapeutics, Inc. (NMRA)

$1.49 -4.49% NASDAQ: NMRA · 15-min delayed
  • WATERTOWN, Massachusetts
  • Public · NASDAQ: NMRA
  • 92 employees
$302.0MMarket cap
-$236.9MNet income
92Employees
NMRANASDAQ
2023IPO

About Neumora Therapeutics, Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$236.9M
Total assets
$191.0M
Market cap
$302.0M

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$0
Operating expenses
$241.2M
Operating income
-$241.2M
Income tax
$130.0K
Net income
-$236.9M
EPS (basic)
$-1.45
EPS (diluted)
$-1.45

Balance sheet

Total assets
$191.0M
Current assets
$190.5M
Total liabilities
$87.2M
Current liabilities
$32.5M
Shareholders’ equity
$103.9M

Cash flow

Operating cash flow
-$206.4M
Investing cash flow
$168.5M
Financing cash flow
$77.1M
Net cash flow
$39.2M

Statements via Polygon.io (SEC filings)

NASDAQ: NMRA
$1.49 -4.49%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.73 $3.59

52-week range

Market cap
$302.0M
EPS (diluted)
$-1.45
Shares outstanding
202.7M
Open
Day range
Prev close
Volume
IPO date
Sep 15, 2023

Neumora Therapeutics, Inc. (NMRA) Stock Price

  • Reported a net loss of $236.9M.
  • Trading 58% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Neumora Therapeutics, Inc..

Write a review
Newsroom

News about Neumora Therapeutics, Inc.

News & sentiment via Polygon.io

FAQ

Neumora Therapeutics, Inc.: frequently asked questions

Is Neumora Therapeutics, Inc. an American company?

Neumora Therapeutics, Inc. is a US-based company headquartered in Watertown, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Neumora Therapeutics, Inc. headquartered?

Neumora Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States.

Is Neumora Therapeutics, Inc. publicly traded?

Yes — Neumora Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol NMRA on the NASDAQ.

What does Neumora Therapeutics, Inc. do?

Neumora Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →